BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Tacere's shRNA Drug for HCV Subject of $145M Pfizer Deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Tacere's shRNA Drug for HCV Subject of $145M Pfizer Deal
Jan. 8, 2008
By
Trista Morrison
No Comments
Tacere Therapeutics Inc. teamed up with Pfizer Inc. to develop and commercialize TT-033, a preclinical hepatitis C drug consisting of three short-hairpin RNAs (shRNAs) delivered within an adeno-associated virus (AAV) protein coat. (BioWorld Today)
BioWorld